<DOC>
	<DOCNO>NCT02498665</DOCNO>
	<brief_summary>This multicenter , open label , Phase 1 dose-escalation study DSP-7888 Dosing Emulsion administer adult patient advanced malignancy . Patients administer escalate dos DSP-7888 Dosing Emulsion intradermally subcutaneously accordance follow regimen : weekly four week Induction Phase , every 7 14 day 6 week Consolidation Phase , every 14 28 day discontinuation criterion meet Maintenance Phase .</brief_summary>
	<brief_title>A Study DSP-7888 Dosing Emulsion Adult Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed write informed consent must obtain document accord International Conference Harmonisation ( ICH ) local regulatory requirement 2 . Patient one follow histologically cytologically confirm advanced malignancy : acute myeloid leukemia ( AML ) , myelodysplastic syndrome ( MDS ) , glioblastoma multiforme ( GBM ) , melanoma , nonsmall cell lung cancer ( NSCLC ) , ovarian cancer , pancreatic cancer , sarcoma , renal cell carcinoma ( RCC ) 3 . Patient must meet least one follow criterion : a. Progressed recurrent despite standard therapy , b . No standard therapy exist malignancy , c. Patient intolerant standard therapy , d. Patient candidate standard therapy , e. For AML MDS patient : patient candidate allogeneic hematopoietic stem cell transplantation , f , For sarcoma patient : f1 . Patient disease metastatic unresectable , f2 . Patient metastatic disease least one prior line therapy metastatic disease , f3 . No curative multimodality option exist 4 . Patients must positive least one follow human leukocyte antigen ( HLA ) : a. HLAA*02:01 , b. HLAA*02:06 , c. HLAA*24:02 5 . ≥ 18 year age 6 . For patient solid tumor , one follow must apply : . Patient measurable disease define immunerelated response criterion ( irRC ) , b . Patient ovarian cancer disease evaluable CA125 7 . For patient solid tumor , follow criterion apply : a. Hemoglobin ≥ 9.0 g/dl , b . Absolute lymphocyte count ≥ 1.0 x 10^9/L , c. Absolute neutrophil count ≥ 1.5 x 10^9/L , d. Platelets ≥ 100.0 x 10^9/L 8 . Patients MDS must diagnose MDS WHO ( 4th edition ) FrenchAmericanBritish ( FAB ) classification 9 . Patients MDS must meet one follow International Prognostic Scoring System ( IPSS ) criterion : a. IPSS score ≥ 1.5 , b. IPSS score &lt; 1.5 patient 's condition remain uncontrolled supportive therapy alone , opinion investigator 10 . For patient AML MDS , patient must white blood cell count ( WBC ) ≤ 50,000/mL . Hydroxyurea allow achieve change must discontinue minimum five ( 5 ) day prior baseline evaluation 11 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 12 . Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 180 day DSP7888 Dosing Emulsion dose 13 . Females childbearing potential must negative serum pregnancy test 14 . Total bilirubin ≤ 2.0 mg/dL ( ≤ 3.0 mg/dL patient know Gilbert 's syndrome ) 15 . Aspartate Aminotransferase ( AST ) ≤ 3.0x upper limit normal ( ULN ) 16 . Alanine transaminase ( ALT ) &lt; 3.0x upper limit normal ( ULN ) 17 . Creatinine ≤ 2.0x ULN 18 . Life expectancy ≥ 3 month 19 . For patient solid tumor , either archival tumor tissue must available patient must consent undergo onstudy tumor biopsy administration first dose 1 . Patient extensively disseminate primary glioblastoma 2 . Patient acute promyelocytic leukemia ( APML ) 3 . For AML MDS patient : patient dry tap bone marrow aspiration screen 4 . Patient symptomatic brain metastasis ( i.e. , metastasis accompany neurological symptom require treatment corticosteroid ) 5 . Patient infection require treatment systemic antibiotic antiviral medication complete treatment infection within 14 day prior plan first dose study drug 6 . Patient require systemic , pharmacologic dos corticosteroid ( equivalent &gt; 30 mg hydrocortisone/day ) Note : Replacement dos ( equivalent ≤ 5 mg prednisone/day ) , topical , ophthalmic , inhalation steroid permit need 7 . Patient positive test Hepatitis B surface antigen , Hepatitis C antibody , human immunodeficiency virus HIV1 HIV2 antibody , history positive result hepatitis C virus ( HCV ) HIV 8 . Patient receive follow treatment within specify timeframes : . Surgery , radiotherapy , chemotherapy ( include moleculartargeted drug ) : 4 week ( 28 day ) , b. Immunosuppressants cytokine formulation ( exclude GCSF ) : 4 week ( 28 day ) , c. Endocrine therapy immunotherapy ( include biological response modifier therapy ) : 2 week ( 14 day ) 9 . Patient unresolved ≥ Grade 2 adverse event ( AE ) previous antineoplastic treatment , exclude alopecia phlebitis 10 . Patient surgery within 4 week prior first dose 11 . Woman pregnant lactate positive pregnancy test screening . If woman positive pregnancy test , evaluation may conduct rule ongoing pregnancy allow patient eligible 12 . Patient concurrent autoimmune disease history chronic recurrent autoimmune disease ; include limited : multiple sclerosis , Grave 's disease , vasculitis , systemic lupus erythematosus , rheumatoid arthritis , systemic sclerosis , myasthenia gravis , ankylose spondylitis , Wegener 's granulomatosis , ulcerative colitis , Crohn 's disease , psoriasis require systemic therapy , pemphigus , temporal arteritis , dermatomyositis , Sjögren 's syndrome , Goodpasture 's syndrome , interstitial pneumonitis , interstitial nephritis , HenochSchönlein purpura 13 . Patient , opinion treat investigator , intercurrent condition could pose undue medical hazard interfere interpretation study result ; condition include , limited : congestive heart failure ( New York Heart Association ( NYHA ) Class III IV ) , unstable angina , cardiac arrhythmia require treatment , recent ( within prior 6 month ) myocardial infarction , acute coronary syndrome stroke , severe obstructive pulmonary disease , hypertension require 2 medication adequate control , diabetes mellitus 2 episode ketoacidosis prior 12 month 14 . Patient Common Toxicity Criteria Adverse Effects ( CTCAE ) v 4.0 grade ≥ 2 hemorrhage 15 . Patient pleural effusion , ascites , pericardial fluid require drainage Note : Patient drain removal ≥ 14 day prior plan first dose study drug sign worsen eligible 16 . Patient medical , psychiatric , social condition , include substance abuse , opinion investigator would preclude compliance requirement study 17 . Patients two active malignancy ( synchronous multiple cancer , metachronous multiple cancer diseasefree period ≤ 5 year , exception carcinoma situ , mucosal carcinoma , carcinomas curatively treated local therapy ) 18 . Patient previous treatment study drug Wilms ' tumor 1 ( WT1 ) relate immune therapy 19 . Patient history allergy oily drug product 20 . Patient known hypersensitivity component study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Wilms ' Tumor 1</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Neoplasms</keyword>
</DOC>